SCHEMBL3638890

SCHEMBL3638890

CCCc1onc(-c2c(Cl)cccc2Cl)c1CCl

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 5/20 0.48
NR1H4 Q96RI1 5/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 4/20 0.40
TSHR P16473 1/20 0.40
SCN5A Q14524 1/20 0.40
SCN9A Q15858 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.40
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
PKM P14618 1/20 0.39
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.38
MAPK1 P28482 1/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12168922 0.90 GHSR (0.49) GHSRNR1H4L3MBTL1TDP1ALDH1A1
SCHEMBL3638644 0.87 GHSR (0.50) GHSRNR1H4L3MBTL1TDP1ALDH1A1
SCHEMBL4332286 0.85 GHSR (0.47) GHSRNR1H4L3MBTL1TDP1ALDH1A1
SCHEMBL4335252 0.83 GHSR (0.50) GHSRNR1H4L3MBTL1TDP1ALDH1A1
SCHEMBL3637567 0.81 GHSR (0.51) GHSRNR1H4L3MBTL1TDP1ALDH1A1
SCHEMBL4339365 0.79 GHSR (0.42) GHSRNR1H4L3MBTL1TDP1ALDH1A1
SCHEMBL22790395 0.79 TDP1 (0.53) GHSRNR1H4L3MBTL1TDP1ALDH1A1
SCHEMBL2304253 0.78 L3MBTL1 (0.59) NR1H4L3MBTL1TDP1ALDH1A1TSHR
SCHEMBL12168917 0.78 GHSR (0.45) GHSRNR1H4L3MBTL1TDP1ALDH1A1
SCHEMBL3642232 0.77 GHSR (0.49) GHSRNR1H4L3MBTL1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3256468-B1 TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2020-04-08 EP disclosed
US-10183917-B2 Tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-01-22 US disclosed
EP-2173174-A1 FARNESOID X RECEPTOR AGONISTS GlaxoSmithKline LLC (US) 2010-04-14 EP disclosed
EP-2170072-A1 FARNESOID X RECEPTOR AGONISTS GlaxoSmithKline LLC (US) 2010-04-07 EP disclosed
EP-2079307-A2 FARNESOID X RECEPTOR AGONISTS SmithKline Beecham Corporation (US) 2009-07-22 EP disclosed
WO-2009005998-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2009-01-08 WO disclosed
WO-2008157270-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed
EP-1962838-A2 FARNESOID X RECEPTOR AGONISTS Smithkline Beecham Corporation (US) 2008-09-03 EP disclosed
WO-2008051942-A2 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-02 WO disclosed
WO-2007076260-A2 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183917-B2 Tricyclic compounds and uses thereof in medicine NR1H4, SLC10A1, SLC10A2 GHSR 896/4885NR1H4 1/4885L3MBTL1 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.